Table 2. Immunophenotype of KRAS Allelic Variants in Biliary Tract Cancers by Site.
| Characteristic | IHCC, No. (%) | EHCC, No. (%) | GBC, No. (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| G12D | G12V | Q61H | G12D | G12V | Q61H | G12D | G12V | Q61H | |
| Total No. | 633 | 333 | 128 | 215 | 141 | 30 | 104 | 45 | 15 |
| Sex | |||||||||
| Males | 349 (55) | 170 (51) | 68 (53) | 118 (55) | 84 (60) | 20 (67) | 33 (22) | 22 (49) | 5 (33) |
| Females | 284 (45) | 163 (49) | 60 (47) | 97 (45) | 57 (40) | 10 (33) | 71 (68) | 23 (51) | 10 (67) |
| Median (IQR) age, y | 64 (25 to ≥89) | 65 (23 to ≥89) | 68 (28 to 85) | 66 (31 to ≥89) | 64 (34 to ≥89) | 64.5 (31 to 86) | 67 (34 to ≥89) | 68 (41 to ≥89) | 67 (30 to 84) |
| GA or tumor, No. | 4.3 | 4.3 | 4.4 | 4.1 | 4.2 | 3.8 | 5.4 | 5 | 4.9 |
| TMB | |||||||||
| No. | 633 | 333 | 128 | 215 | 141 | 30 | 104 | 45 | 15 |
| Median (IQR) | 1.2 (0-2.5) | 1.2 (0.9-2.6) | 1.2 (0-2.5) | 1.2 (0-2.5) | 1.2 (0-2.1) | 1.2 (0-2.5) | 1.5 (0-3.8) | 2.5 (1.2-3.8) | 2.5 (1.7-4.4) |
| Mean (SD) | 2.1 (3.0) | 2.2 (2.8) | 2.4 (4.1) | 1.8 (3.0) | 1.6 (3.7) | 1.5 (1.5) | 2.7 (3.2) | 3.3 (5.3) | 3.1 (2.0) |
| ≥10 variants/Mb | 16 (3) | 7 (1) | 3 (2) | 3 (1) | 2 (1) | 0 | 5 (5) | 2 (4) | 0 |
| ≥20 variants/Mb | 3 (1) | 2 (1) | 3 (2) | 1 (1) | 1 (1) | 0 | 1 (1) | 1 (2) | 0 |
| PD-L1 IHCC | |||||||||
| No. | 158 | 87 | 28 | 53 | 34 | 10 | 29 | 12 | 6 |
| Negativity | 99 (63) | 59 (67) | 13 (46) | 31 (58) | 25 (73) | 8 (80) | 15 (52) | 5 (42) | 3 (50) |
| Low | 46 (29) | 24 (28) | 12 (43) | 19 (36) | 9 (27) | 2 (20) | 9 (31) | 6 (50) | 1 (17) |
| High | 13 (8) | 4 (5) | 3 (11) | 3 (6) | 0 | 0 | 5 (17) | 1 (8) | 2 (33) |
| MSI | |||||||||
| No. | 608 | 320 | 124 | 204 | 137 | 28 | 101 | 45 | 13 |
| MSI-High | 7 (1) | 2 (1) | 2 (2) | 1 (1) | 2 (2) | 0 | 3 (3) | 1 (2) | 0 |
Abbreviations: EHCC, extrahepatic cholangiocarcinoma; GA, genomic alterations; GBC, gallbladder cancer; IHCC, intrahepatic cholangiocarcinoma; Mb, megabase; PD-L1, programmed death 1 ligand 1; MSI, microsatellite instability; TMB, tumor mutational burden.